AndtbackaRHKaufmanHLCollichioF, et al.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780-2788. doi:10.1200/JCO.2014.58.3377Epub 2015 May 26. PMID: 26014293.
2.
ChesneyJImbert-FernandezYTelangS, et al.Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Res. 2018;28(3):250-255.
3.
ChesneyJARibasALongGV, et al.Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41(3):528-540. doi:10.1200/JCO.22.00343Epub 2022 Aug 23. PMID: 35998300; PMCID: PMC9870217.
4.
DummerRGyorkiDEHyngstromJ, et al.Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021;27(10):1789-1796. doi:10.1038/s41591-021-01510-7Epub 2021 Oct 4. PMID: 34608333.
